Matridx Closes ￥200 Miilion Series B Financing, Focusing on Precision Diagnotics of Infection

(VCBeat) Jan. 20, 2021-- Matridx Biotechnology Co., Ltd. ("Matridx") has recently announced the close of a ￥200 million Series B investment round, led by CD Capital, with participation from Qianhai FOF. Previous investors including Proxima Ventures, Puhua Capital, and senior professionals in the in vitro diagnostics (IVD) industry also joined the latest round. The fresh round of funding will be used towards the registration and certification of medical devices for infection, the development of new products and commercialization.

Matridx was co-founded by Dr. Wang Jun, one of the founding team members of Berry Genomics and Mr. Zhong Jie, the original partners of the Zhejiang Grand Health Industry Equity Investment Fund. As a technology platform based on NGS (Next-Generation Sequencing) and gene editing by CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats) /Cas (CRISPR-associated), Matridx is committed to the innovation of infectious disease testing. 

Through years of R&D and clinical studies, Matridx has successfully developed the world's leading intelligent solution of automatic detection for pathogen metagenomics, and launched the Q-mNGS quantitative metagenomics analysis project as the first company in China. According to the research results, the Q-mNGS approach developed by Matridx has faster speed, more accurate test results and wider detection service coverage in China. which has applied for both patents and other intellectual property rights nearly 20.

Matridx is the strategic partner of Ali Cloud in the AI-based application of infectious diseases, and the partner of Illumina, the global leader in gene sequencing, in the microbiome field.

CD Capital is a venture capital firm specialized in life sciences and medical technology. It is currently managing both RMB and USD funds with a total size of $600 million. The company has made over 40 investments with high growth potential and earned a reputation as a premier venture capital firm with the main focus on China healthcare industry.

Qianhai FOF was founded in 2015 and is headquartered in Shenzhen, China, with a current fundraising scale of 28.5 billion yuan. It is a fund management company that markets qualified investors in the private equity investment industry. The company pursues low-risk, medium-to-high-yield, mainly based on high-quality venture capital, and private equity investment funds, supplemented by direct investment and short-term investment.